The anticholinergic medication index and dementia risk: evidence from the UK Biobank and All of Us research program



Asiimwe, Innocent Gerald ORCID: 0000-0002-1196-1822, Best, Kate, Sofat, Reecha, Todd, Oliver M, Walker, Lauren, Jorgensen, Andrea L ORCID: 0000-0002-6977-9337, Clegg, Andrew and Pirmohamed, Munir ORCID: 0000-0002-7534-7266
(2025) The anticholinergic medication index and dementia risk: evidence from the UK Biobank and All of Us research program AGE AND AGEING, 54 (11). afaf326-. ISSN 0002-0729, 1468-2834

Access the full-text of this item by clicking on the Open Access link.

Abstract

Introduction: Anticholinergic drugs are associated with adverse effects, including cognitive decline. In this study, we externally validated the Anticholinergic Medication Index (ACMI) by investigating the association between baseline anticholinergic burden and dementia risk in two large prospective cohorts: the UK Biobank (UKB) and the US All of Us (AoU) program. Methods: We analysed data from the UKB (n =125 260; study period, 2000–15) and AoU (92 047; 2000–22). Cox proportional hazards models, adjusted for clinical and genetic covariates with death as a competing risk, assessed the association between baseline annual ACMI-computed anticholinergic burden and dementia risk. Exploratory genetic analyses included candidate gene analysis of acetylcholine signalling pathway genes in the UKB and development of a polygenic hazard score in AoU. Results: Prescription of any of the 88 ACMI-listed drugs at baseline was associated with increased dementia risk (UKB HR: 1.15, 95% CI 1.09–1.21; AoU: 1.06, 1.04–1.09) and mortality (UKB: 1.23, 1.19–1.27; AoU: 1.16, 1.13–1.19). We replicated the genetic influence of APOE on dementia risk (UKB [APOE ε4 vs ε3 carriers] HR: 2.05, 1.86–2.26; AoU: 1.61, 1.44–1.80). No significant gene–drug interactions were identified. Conclusion: Higher baseline ACMI scores were associated with increased risks of dementia and mortality in two large cohorts, providing external validation of the ACMI. While causal inference is not possible, these findings support the ACMI’s potential utility as a prognostic tool for risk stratification and for informing future work on safer prescribing.

Item Type: Article
Uncontrolled Keywords: ACMI, anticholinergic burden, All of Us Research Program, dementia, UK Biobank, older people
Divisions: Faculty of Health & Life Sciences
Faculty of Health & Life Sciences > Inst. Population Health
Faculty of Health & Life Sciences > Inst. Population Health > Health Data Science
Faculty of Health & Life Sciences > Inst. Population Health > Inst. Population Health (T&R Staff)
Faculty of Health & Life Sciences > Inst. Systems, Molec & Integrative Biology
Faculty of Health & Life Sciences > Inst. Systems, Molec & Integrative Biology > Inst. Systems, Molec & Integrative Biology (T&R Staff)
Faculty of Health & Life Sciences > Inst. Systems, Molec & Integrative Biology > Pharmacology & Therapeutics
Depositing User: Symplectic Admin
Date Deposited: 19 Nov 2025 16:04
Last Modified: 16 Jun 2026 20:04
DOI: 10.1093/ageing/afaf326
Open Access URL: https://doi.org/10.1093/ageing/afaf326
Related Websites:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3195515
Disclaimer: The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.